Literature DB >> 27665172

The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients.

He Cheng1, Guopei Luo2, Yu Lu2, Kaizhou Jin2, Meng Guo2, Jin Xu2, Jiang Long2, Liang Liu2, Xianjun Yu3, Chen Liu4.   

Abstract

BACKGROUND: The systemic inflammation response and immune impairment are closely related to the development and progression of various tumours, such as pancreatic cancer. In this study, we evaluated circulating inflammation factors and circulating regulatory T cells (Tregs) as markers of immunosuppression in a cohort of Chinese patients with resectable pancreatic cancer.
METHODS: Samples were retrospectively collected from a series of 195 pathological stage I/II pancreatic cancer patients who underwent potentially curative surgery between June 2010 and April 2014. To examine the prognostic factors, circulating systemic inflammation-based markers and Tregs, detected by flow cytometry, were analysed.
RESULTS: Univariate analyses revealed that the neutrophil-lymphocyte ratio (NLR), TNM stage, differentiation, chemotherapy, CA19-9 levels and presence of Tregs are significantly associated with overall survival in patients with resectable pancreatic cancers. NLR (p = 0.001, HR = 0.538), TNM stage (p = 0.004, HR = 0.593), differentiation (p = 0.011, HR = 0.46), chemotherapy (p = 0.006, HR = 0.516) and Tregs (p = 0.001, HR = 0.558) are identified as independent prognostic markers by multivariate analyses. Interestingly, we also found that high NLR levels combined with a high proportion of Tregs (p < 0.001, HR = 3.521) correlate strongly with worse survival, with a greater than 3.5-fold increased risk of death compared with those with concurrent low levels of NLR and Tregs.
CONCLUSIONS: The preoperative NLR and circulating regulatory T cells are potentially independent prognostic factors for overall survival in resectable pancreatic cancer patients. High NLR levels combined with poor immune state before surgery, as measured by Tregs, are associated with an extremely poor prognosis.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Inflammation response; Neutrophil-lymphocyte ratio (NLR); Pancreatic cancer; Prognosis; Regulatory T cells (Tregs)

Mesh:

Substances:

Year:  2016        PMID: 27665172     DOI: 10.1016/j.pan.2016.09.007

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  23 in total

1.  Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer.

Authors:  Yuan Gao; Wen-Jie Wang; Qiaoming Zhi; Meng Shen; Min Jiang; Xiaojie Bian; Fei-Ran Gong; Chong Zhou; Lian Lian; Meng-Yao Wu; Jun Feng; Min Tao; Wei Li
Journal:  Oncotarget       Date:  2017-09-27

2.  Microsatellite Instability Correlated Inflammatory Markers and their Prognostic Value in the Rectal Cancer Following Neoadjuvant Chemoradiotherapy: A Hypothesis-generating Study.

Authors:  Joo Ho Lee; Byung-Hee Kang; Changhoon Song; Sung-Bum Kang; Hye Seung Lee; Keun-Wook Lee; Eui Kyu Chie; Jae-Sung Kim
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Risk factors and prognostic index model for pancreatic cancer.

Authors:  Hui Huang; Jichun Sun; Zheming Jiang; Xianlin Zhang; Zheng Li; Hongwei Zhu; Xiao Yu
Journal:  Gland Surg       Date:  2022-01

4.  Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.

Authors:  Shuichi Ota; Mamiko Miyashita; Yuka Yamagishi; Masahiro Ogasawara
Journal:  Hum Vaccin Immunother       Date:  2021-12-17       Impact factor: 3.452

5.  Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Differentiated Thyroid Carcinoma Having Distant Metastasis: A Comparison With Thyroglobulin-doubling Rate and Tumor Volume-doubling Rate.

Authors:  Yasuhiro Ito; Naoyoshi Onoda; Minoru Kihara; Akihiro Miya; Akira Miyauchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

6.  Pancreatic Tumor Microenvironment.

Authors:  Kai Wang; Hong He
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  The Prognostic Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Resected Patients with Pancreatic Adenocarcinoma.

Authors:  Le-Ping Fang; Xiao-Yan Xu; Yu Ji; Pu-Wen Huang
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

8.  Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.

Authors:  Yun-Gyoo Lee; Hyun Chang; Bhumsuk Keam; Sang Hoon Chun; Jihyun Park; Keon Uk Park; Seong Hoon Shin; Ho Jung An; Kyoung Eun Lee; Keun-Wook Lee; Hye Ryun Kim; Sung-Bae Kim; Myung-Ju Ahn; In Gyu Hwang
Journal:  Cancer Res Treat       Date:  2020-12-07       Impact factor: 4.679

9.  CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis.

Authors:  Alessandro Coppola; Vincenzo La Vaccara; Michele Fiore; Tommaso Farolfi; Sara Ramella; Silvia Angeletti; Roberto Coppola; Damiano Caputo
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

10.  The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.

Authors:  Rixiong Wang; Nan Lin; Binbin Mao; Qing Wu
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-23       Impact factor: 4.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.